Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude …

…, A Broniscer, R Krance, GA Hale, CF Stewart… - The lancet …, 2006 - thelancet.com
Background Current treatment for medulloblastoma, which includes postoperative radiotherapy
and 1 year of chemotherapy, does not cure many children with high-risk disease. We …

[PDF][PDF] Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/− p53−/− mice

…, K Sasai, C Fuller, H Baines, M Connelly, CF Stewart… - Cancer cell, 2004 - cell.com
Medulloblastoma is the most common malignant pediatric brain tumor. Current treatment is
associated with major long-term side effects; therefore, new nontoxic therapies, targeting …

Mrp4 confers resistance to topotecan and protects the brain from chemotherapy

…, B Johnston, RJ Scheper, CF Stewart… - … and cellular biology, 2004 - Taylor & Francis
The role of the multidrug resistance protein MRP4/ABCC4 in vivo remains undefined. To
explore this role, we generated Mrp4-deficient mice. Unexpectedly, these mice showed …

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered …

…, NL Hagedorn, MB McCarville, CF Stewart… - Clinical cancer …, 2007 - AACR
Purpose: Dysfunctional tumor vessels can be a significant barrier to effective cancer therapy.
However, increasing evidence suggests that vascular endothelial growth factor (VEGF) …

[HTML][HTML] Vismodegib exerts targeted efficacy against recurrent sonic hedgehog–subgroup medulloblastoma: results from phase II pediatric brain tumor consortium …

…, SJ Allen, A Onar-Thomas, CF Stewart… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Two phase II studies assessed the efficacy of vismodegib, a sonic hedgehog (SHH)
pathway inhibitor that binds smoothened (SMO), in pediatric and adult recurrent …

Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

…, GS Germain, FC Harwood, JD Schuetz, CF Stewart… - Cancer research, 2004 - AACR
Imatinib mesylate (Gleevec, STI571) is a kinase inhibitor selective for Bcr-Abl, activated c-Kit
kinases, and platelet-derived growth factor receptor tyrosine kinase. Imatinib mesylate, …

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre …

…, G Dhall, P Baxter, SG Kreissman, CF Stewart… - The lancet …, 2019 - thelancet.com
Background Paediatric low-grade glioma is the most common CNS tumour of childhood.
Although overall survival is good, disease often recurs. No single universally accepted …

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium …

…, IF Pollack, S Goldman, LA Doyle, CF Stewart… - Neuro …, 2017 - academic.oup.com
Background. Activation of the mitogen-activated protein kinase pathway is important for
growth of pediatric low-grade gliomas (LGGs). The aim of this study was to determine the …

[PDF][PDF] Medulloblastoma genotype dictates blood brain barrier phenotype

…, S Perreault, E Wadhwa, YJ Cho, CF Stewart… - Cancer cell, 2016 - cell.com
The childhood brain tumor, medulloblastoma, includes four subtypes with very different
prognoses. Here, we show that paracrine signals driven by mutant β-catenin in WNT-…

[HTML][HTML] Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial …

…, R Cohn, MJ Fisher, MJ Krasin, CF Stewart… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
RESULTS Three hundred thirty eligible patients with medulloblastoma were enrolled. Five-year
PFS was 83.2%(95% CI, 78.4 to 88.2) for average-risk patients (n= 227) and 58.7%(95% …